All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
During the European Hematology Association 2024 Hybrid Congress, Andreas Reiter shared 3-year follow up data from the phase II PATHFINDER study of avapritinib for the treatment of patients with advanced systemic mastocytosis (AdvSM). |
Key learnings |
The overall response and complete response rates were numerically higher in the treatment-naïve setting (87% and 43%, respectively) vs in patients with ≥1 prior systemic therapy (66% and 21%, respectively). |
Median overall survival (OS) was not reached, regardless of AdvSM subtype or treatment history. |
The 36-month OS rate was 75%, with more favorable data for the treatment-naïve vs pre-treated cohort. |
No new safety concerns were identified during the follow up period, with most adverse events manageable with dose reduction or interruption. |
Data from PATHFINDER suggest avapritinib as a feasible treatment option in AdvSM, particularly in early lines of therapy. |
Your opinion matters
Subscribe to get the best content related to MPN delivered to your inbox